Editas Medicine’s Q3 GAAP EPS of -$0.81 beats estimates by $0.07

Trending News 🌥️

EDITAS ($NASDAQ:EDIT): The company’s Q3 GAAP EPS of -$0.81 beats estimates by $0.07.

Earnings

This is the second consecutive quarter that the company has beaten earnings estimates. In the earning report of FY2022 Q2 as of June 30, Editas Medicine earned 31.8M USD in total revenue, lost 184.5M USD in net income. Compared to the previous year, there was a 24.7% increase in total revenue.

Editas Medicine’s total revenue reached from 90.7M USD to 31.8M USD in the last 3 years. The company’s focus on innovation and developing new treatments has helped it to grow despite the challenges posed by the pandemic.

Share Price

On Wednesday, Editas Medicine stock opened at $13.0 and closed at $12.9, up by 1.1% from last closing price of 12.8. Editas Medicine is a clinical-stage biotechnology company that focuses on developing transformative genomic medicines to treat serious diseases. The company’s mission is to translate the power and potential of the genome editing into a robust pipeline of treatments for patients with serious diseases.

VI Analysis

According to the data from the VI app, EDITAS MEDICINE is a high risk investment in terms of financial and business aspects. The app has detected 4 risk warnings in income sheet, balance sheet, cashflow statement, and non-financial aspects. The company’s fundamentals reflect its long term potential, but the risks involved should be considered before making any investment decisions.

VI Peers

In the world of gene-editing, three companies have emerged as leaders in the race to develop CRISPR-based treatments: Editas Medicine Inc, Intellia Therapeutics Inc, and CRISPR Therapeutics AG. All three companies are working on treatments for a variety of diseases, ranging from cancer to blindness. However, only Editas has begun to clinical trials on humans. This gives them a significant advantage over their competitors. While all three companies are working on cutting-edge science, Editas is in the lead to bring these treatments to market.

– Intellia Therapeutics Inc ($NASDAQ:NTLA)

Intellia Therapeutics Inc is a genomic editing company. Its technology involves the use of meganucleases and CRISPR/Cas9 to edit genomes. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.

As of 2022, Intellia Therapeutics Inc has a market cap of 4.19B and a Return on Equity of -43.06%. The company’s technology involves the use of meganucleases and CRISPR/Cas9 to edit genomes. Intellia Therapeutics Inc was founded in 2014 and is headquartered in Cambridge, Massachusetts.

– CRISPR Therapeutics AG ($NASDAQ:CRSP)

CRISPR Therapeutics AG is a clinical-stage biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases. Its proprietary CRISPR/Cas9 platform enables it to target and edit genes with precision. The company is advancing a broad portfolio of first-in-class gene-edited therapies in hemoglobinopathies, oncology, and rare diseases.

– Beam Therapeutics Inc ($NASDAQ:BEAM)

Beam Therapeutics Inc is a clinical-stage biotechnology company. The Company focuses on developing precision genetic medicines through its proprietary base editing technology. Its product candidates include BTX-A51, BTX-A52, BTX-B18, BTX-B19 and BTX-B20. The Company’s base editor technology enables it to make precise, predictable and permanent changes to single base nucleotides in genomic DNA without making double-stranded breaks or requiring a donor template.

Summary

Investing in Editas Medicine may be a good way to gain exposure to the cutting-edge field of gene editing. The company is a leader in developing CRISPR-based therapies and is working on treatments for a range of diseases. Editas Medicine’s share price has been volatile in recent years, but the company’s long-term prospects look promising.